Nicholas J. Donato
About
In The Last Decade
Nicholas J. Donato
110 papers receiving 6.6k citations
Hit Papers
Peers
Comparison fields: 5 of 113
- Molecular Biology 3.3k
- Hematology 2.5k
- Oncology 2.0k
- Genetics 1.8k
- Rheumatology 1.2k
Countries citing papers authored by Nicholas J. Donato
This map shows the geographic impact of Nicholas J. Donato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas J. Donato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas J. Donato more than expected).
Fields of papers citing papers by Nicholas J. Donato
This network shows the impact of papers produced by Nicholas J. Donato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas J. Donato. The network helps show where Nicholas J. Donato may publish in the future.
Co-authorship network of co-authors of Nicholas J. Donato
This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas J. Donato. A scholar is included among the top collaborators of Nicholas J. Donato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas J. Donato. Nicholas J. Donato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 49 | |
| 2 | 50 | |
| 3 | 39 | |
| 4 | 41 | |
| 5 | 317 | |
| 6 | Degradation of c-Myc by WP1130 Through Activation of a Novel Proteasomal-Dependent Pathway | 1 |
| 7 | Anti-tumor effects of combination therapy with anti-EGFR and anti-Src therapy in colorectal cancer | 1 |
| 8 | The preclinical pharmacology of WP1066, a potent small molecule inhibitor of the JAK2/STAT3 pathway | 10 |
| 9 | Combined activity of dasatinib (BMS-354825) and oxaliplatin in an orthotopic model of metastatic colorectal carcinoma | 4 |
| 10 | 15 | |
| 11 | Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668 | 3 |
| 12 | The protein-tyrosine phosphatase SHP1 is downregulated with disease progression in Philadelphia (Ph) chromosome positive chronic myelogenous leukemia (CML), and effect not mediated by DNA methylation | 1 |
| 13 | 25 | |
| 14 | 414 | |
| 15 | Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor–κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis breakdown → | 596 |
| 16 | 18 | |
| 17 | 16 | |
| 18 | 21 | |
| 19 | 15 | |
| 20 | 52 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.